Delgocitinib 2% Cream Therapeutic Cheat Sheet
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that represents a novel non-steroidal treatment mechanism for chronic hand dermatitis. As a pan-JAK inhibitor, delgocitinib blocks all four members of the JAK family (JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2)), thus simultaneously modulating the many cytokine pathways that drive chronic inflammatory skin disorders. Delgocitinib was in …
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that represents a novel non-steroidal treatment mechanism for chronic hand dermatitis. As a pan-JAK inhibitor, delgocitinib blocks all four members of the JAK family (JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2)), thus simultaneously modulating the many cytokine pathways that drive chronic inflammatory skin disorders. Delgocitinib was in … Continue reading "Delgocitinib 2% Cream Therapeutic Cheat Sheet"
Abrocitinib is an oral, once-daily selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis. It can provide rapid improvement in pruritus and skin disease and is a useful treatment option for many patients. As an oral medication, it may also be preferred by patients who want to avoid injections. When prescribing abrocitinib, it is important to discuss laboratory … 
Tranexamic acid (TXA) is a synthetic lysine derivative that reversibly blocks the lysine-binding site on plasminogen, preventing conversion to plasmin. While originally developed as an antifibrinolytic agent to reduce bleeding, TXA has several downstream effects that make it useful in dermatology, particularly for pigmentary disorders, with emerging evidence in inflammatory disorders as well. TX … 
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. … 
Cabtreo is the first FDA-approved fixed-dose triple-combination topical treatment for acne vulgaris, pairing a lincosamide antibiotic (clindamycin), a synthetic retinoid (adapalene), and a keratolytic oxidizing agent (benzoyl peroxide) into a single once-daily gel. This formulation targets several pillars of acne pathogenesis simultaneously: cutaneous C. acnes proliferation, abnormal keratinizatio …